1
|
Yoo EJ, Kim JS, Stransky S, Spivack S, Sidoli S. Advances in proteomics methods for the analysis of exhaled breath condensate. MASS SPECTROMETRY REVIEWS 2024; 43:713-722. [PMID: 38149478 DOI: 10.1002/mas.21871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 12/13/2023] [Indexed: 12/28/2023]
Abstract
The analysis of exhaled breath condensate (EBC) demonstrates a promising avenue of minimally invasive biopsies for diagnostics. EBC is obtained by cooling exhaled air and collecting the condensation to be utilized for downstream analysis using various analytical methods. The aqueous phase of breath contains a large variety of miscible small compounds including polar electrolytes, amino acids, cytokines, chemokines, peptides, small proteins, metabolites, nucleic acids, and lipids/eicosanoids-however, these analytes are typically present at minuscule levels in EBC, posing a considerable technical challenge. Along with recent improvements in devices for breath collection, the sensitivity and resolution of liquid chromatography coupled to online mass spectrometry-based proteomics has attained subfemtomole sensitivity, vastly enhancing the quality of EBC sample analysis. As a result, proteomics analysis of EBC has been expanding the field of breath biomarker research. We present an au courant overview of the achievements in proteomics of EBC, the advancement of EBC collection devices, and the current and future applications for EBC biomarker analysis.
Collapse
Affiliation(s)
- Edwin J Yoo
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
- Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Julie S Kim
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Stephanie Stransky
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Simon Spivack
- Department of Medicine, Department of Epidemiology & Population Health, Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Simone Sidoli
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| |
Collapse
|
2
|
Peters AA, Solomon JB, von Stackelberg O, Samei E, Alsaihati N, Valenzuela W, Debic M, Heidt C, Huber AT, Christe A, Heverhagen JT, Kauczor HU, Heussel CP, Ebner L, Wielpütz MO. Influence of CT dose reduction on AI-driven malignancy estimation of incidental pulmonary nodules. Eur Radiol 2024; 34:3444-3452. [PMID: 37870625 PMCID: PMC11126495 DOI: 10.1007/s00330-023-10348-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 08/10/2023] [Accepted: 09/03/2023] [Indexed: 10/24/2023]
Abstract
OBJECTIVES The purpose of this study was to determine the influence of dose reduction on a commercially available lung cancer prediction convolutional neuronal network (LCP-CNN). METHODS CT scans from a cohort provided by the local lung cancer center (n = 218) with confirmed pulmonary malignancies and their corresponding reduced dose simulations (25% and 5% dose) were subjected to the LCP-CNN. The resulting LCP scores (scale 1-10, increasing malignancy risk) and the proportion of correctly classified nodules were compared. The cohort was divided into a low-, medium-, and high-risk group based on the respective LCP scores; shifts between the groups were studied to evaluate the potential impact on nodule management. Two different malignancy risk score thresholds were analyzed: a higher threshold of ≥ 9 ("rule-in" approach) and a lower threshold of > 4 ("rule-out" approach). RESULTS In total, 169 patients with 196 nodules could be included (mean age ± SD, 64.5 ± 9.2 year; 49% females). Mean LCP scores for original, 25% and 5% dose levels were 8.5 ± 1.7, 8.4 ± 1.7 (p > 0.05 vs. original dose) and 8.2 ± 1.9 (p < 0.05 vs. original dose), respectively. The proportion of correctly classified nodules with the "rule-in" approach decreased with simulated dose reduction from 58.2 to 56.1% (p = 0.34) and to 52.0% for the respective dose levels (p = 0.01). For the "rule-out" approach the respective values were 95.9%, 96.4%, and 94.4% (p = 0.12). When reducing the original dose to 25%/5%, eight/twenty-two nodules shifted to a lower, five/seven nodules to a higher malignancy risk group. CONCLUSION CT dose reduction may affect the analyzed LCP-CNN regarding the classification of pulmonary malignancies and potentially alter pulmonary nodule management. CLINICAL RELEVANCE STATEMENT Utilization of a "rule-out" approach with a lower malignancy risk threshold prevents underestimation of the nodule malignancy risk for the analyzed software, especially in high-risk cohorts. KEY POINTS • LCP-CNN may be affected by CT image parameters such as noise resulting from low-dose CT acquisitions. • CT dose reduction can alter pulmonary nodule management recommendations by affecting the outcome of the LCP-CNN. • Utilization of a lower malignancy risk threshold prevents underestimation of pulmonary malignancies in high-risk cohorts.
Collapse
Affiliation(s)
- Alan A Peters
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany.
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany.
| | - Justin B Solomon
- Carl E. Ravin Advanced Imaging Laboratories, Medical Physics Graduate Program, Clinical Imaging Physics Group, Department of Radiology, Duke University Medical Center, Durham, NC, USA
| | - Oyunbileg von Stackelberg
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| | - Ehsan Samei
- Carl E. Ravin Advanced Imaging Laboratories, Medical Physics Graduate Program, Clinical Imaging Physics Group, Department of Radiology, Duke University Medical Center, Durham, NC, USA
| | - Njood Alsaihati
- Carl E. Ravin Advanced Imaging Laboratories, Medical Physics Graduate Program, Clinical Imaging Physics Group, Department of Radiology, Duke University Medical Center, Durham, NC, USA
| | - Waldo Valenzuela
- University Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
| | - Manuel Debic
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| | - Christian Heidt
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| | - Adrian T Huber
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
| | - Andreas Christe
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
| | - Johannes T Heverhagen
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
- Department of BioMedical Research, Experimental Radiology, University of Bern, Bern, Switzerland
- Department of Radiology, The Ohio State University, Columbus, OH, USA
| | - Hans-Ulrich Kauczor
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| | - Claus P Heussel
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| | - Lukas Ebner
- Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland
| | - Mark O Wielpütz
- Diagnostic and Interventional Radiology, Heidelberg University Hospital, Im Neuenheimer Feld 420, 69120, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
- Department of Diagnostic and Interventional Radiology With Nuclear Medicine, Thoraxklinik at University of Heidelberg, Röntgenstraße 1, 69126, Heidelberg, Germany
| |
Collapse
|
3
|
Leong TL, McWilliams A, Wright GM. Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening. J Thorac Oncol 2024; 19:522-524. [PMID: 38582541 DOI: 10.1016/j.jtho.2024.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 01/02/2024] [Indexed: 04/08/2024]
Affiliation(s)
- Tracy L Leong
- Department of Respiratory Medicine, Austin Health, Heidelberg, Victoria, Australia.
| | - Annette McWilliams
- Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
| | - Gavin M Wright
- Department of Cardiothoracic Surgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia
| |
Collapse
|
4
|
Heideman BE, Kammer MN, Paez R, Swanson T, Godfrey CM, Low SW, Xiao D, Li TZ, Richardson JR, Knight MA, Shojaee S, Deppen SA, Lentz RJ, Grogan EL, Maldonado F. The Lung Cancer Prediction Model "Stress Test": Assessment of Models' Performance in a High-Risk Prospective Pulmonary Nodule Cohort. CHEST PULMONARY 2024; 2:100033. [PMID: 38737731 PMCID: PMC11087042 DOI: 10.1016/j.chpulm.2023.100033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 05/14/2024]
Abstract
BACKGROUND Pulmonary nodules represent a growing health care burden because of delayed diagnosis of malignant lesions and overtesting for benign processes. Clinical prediction models were developed to inform physician assessment of pretest probability of nodule malignancy but have not been validated in a high-risk cohort of nodules for which biopsy was ultimately performed. RESEARCH QUESTION Do guideline-recommended prediction models sufficiently discriminate between benign and malignant nodules when applied to cases referred for biopsy by navigational bronchoscopy? STUDY DESIGN AND METHODS We assembled a prospective cohort of 322 indeterminate pulmonary nodules in 282 patients referred to a tertiary medical center for diagnostic navigational bronchoscopy between 2017 and 2019. We calculated the probability of malignancy for each nodule using the Brock model, Mayo Clinic model, and Veterans Affairs (VA) model. On a subset of 168 patients who also had PET-CT scans before biopsy, we also calculated the probability of malignancy using the Herder model. The performance of the models was evaluated by calculating the area under the receiver operating characteristic curves (AUCs) for each model. RESULTS The study cohort contained 185 malignant and 137 benign nodules (57% prevalence of malignancy). The malignant and benign cohorts were similar in terms of size, with a median longest diameter for benign and malignant nodules of 15 and 16 mm, respectively. The Brock model, Mayo Clinic model, and VA model showed similar performance in the entire cohort (Brock AUC, 0.70; 95% CI, 0.64-0.76; Mayo Clinic AUC, 0.70; 95% CI, 0.64-0.76; VA AUC, 0.67; 95% CI, 0.62-0.74). For 168 nodules with available PET-CT scans, the Herder model had an AUC of 0.77 (95% CI, 0.68-0.85). INTERPRETATION Currently available clinical models provide insufficient discrimination between benign and malignant nodules in the common clinical scenario in which a patient is being referred for biopsy, especially when PET-CT scan information is not available.
Collapse
Affiliation(s)
- Brent E Heideman
- Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Atrium Health Wake Forest Baptist, Winston-Salem, NC
| | - Michael N Kammer
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Rafael Paez
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Terra Swanson
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Caroline M Godfrey
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - See-Wei Low
- Division of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, OH
| | - David Xiao
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Thomas Z Li
- Department of Biomedical Engineering, Vanderbilt University, Nashville, TN
| | - Jacob R Richardson
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Michael A Knight
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Samira Shojaee
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Stephen A Deppen
- Department of Surgery, Tennessee Valley Healthcare System, Veterans Affairs, Nashville, TN; and the Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Robert J Lentz
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Eric L Grogan
- Department of Surgery, Tennessee Valley Healthcare System, Veterans Affairs, Nashville, TN; and the Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Fabien Maldonado
- Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
5
|
Liu JJ, Shen WB, Qin QR, Li JW, Li X, Liu MY, Hu WL, Wu YY, Huang F. Prediction of positive pulmonary nodules based on machine learning algorithm combined with central carbon metabolism data. J Cancer Res Clin Oncol 2024; 150:33. [PMID: 38270703 PMCID: PMC10811045 DOI: 10.1007/s00432-024-05610-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 01/04/2024] [Indexed: 01/26/2024]
Abstract
BACKGROUND Lung cancer causes a huge disease burden, and early detection of positive pulmonary nodules (PPNs) as an early sign of lung cancer is extremely important for effective intervention. It is necessary to develop PPNs risk recognizer based on machine learning algorithm combined with central carbon metabolomics. METHODS The study included 2248 participants at high risk for lung cancer from the Ma'anshan Community Lung Cancer Screening cohort. The Least Absolute Shrinkage and Selection Operator (LASSO) was used to screen 18 central carbon-related metabolites in plasma, recursive feature elimination (RFE) was used to select all 42 features, followed by five machine learning algorithms for model development. The performance of the model was evaluated using area under the receiver operator characteristic curve (AUC), accuracy, precision, recall, and F1 scores. In addition, SHapley Additive exPlanations (SHAP) was performed to assess the interpretability of the final selected model and to gain insight into the impact of features on the predicted results. RESULTS Finally, the two prediction models based on the random forest (RF) algorithm performed best, with AUC values of 0.87 and 0.83, respectively, better than other models. We found that homogentisic acid, fumaric acid, maleic acid, hippuric acid, gluconic acid, and succinic acid played a significant role in both PPNs prediction model and NPNs vs PPNs model, while 2-oxadipic acid only played a role in the former model and phosphopyruvate only played a role in the NPNs vs PPNs model. This model demonstrates the potential of central carbon metabolism for PPNs risk prediction and identification. CONCLUSION We developed a series of predictive models for PPNs, which can help in the early detection of PPNs and thus reduce the risk of lung cancer.
Collapse
Affiliation(s)
- Jian-Jun Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Wen-Bin Shen
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Qi-Rong Qin
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
- Ma'anshan Center for Disease Control and Prevention, Ma'anshan, Anhui, China
| | - Jian-Wei Li
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Xue Li
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Meng-Yu Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Wen-Lei Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Yue-Yang Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Fen Huang
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
| |
Collapse
|
6
|
Wu YY, Shen WB, Li JW, Liu MY, Hu WL, Wang S, Liu JJ, Huang F, Qin QR. Targeted metabolomics reveals the association between central carbon metabolism and pulmonary nodules. PLoS One 2023; 18:e0295276. [PMID: 38060623 PMCID: PMC10703222 DOI: 10.1371/journal.pone.0295276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Accepted: 11/18/2023] [Indexed: 12/18/2023] Open
Abstract
With the widespread application of low-dose computed tomography (LDCT) technology, pulmonary nodules have aroused more attention. Significant alteration in plasma metabolite levels, mainly amino acid and lipid, have been observed in patients of PNs. However, evidence on the association between central carbon metabolism and PNs are largely unknown. The aim of this study was to investigate the underlying association of PNs and plasma central carbon metabolites. We measured the levels of 16 plasma central carbon metabolites in 1954 participants who gained LDCT screening in MALSC cohort. The inverse probability weighting (IPW) technique was used to control for bias due to self-selection for LDCT in the assessed high-risk population. The least absolute shrinkage and selection operator (LASSO) penalized regression was used to deal with the problem of multicollinearity among metabolites and the combined association of central carbon metabolites with PNs was estimated by using quantile g-computation (QgC) models. A quartile increase in 3-hydroxybutyric acid, gluconic acid, succinic acid and hippuric acid was positively associated with the PNs risk, whereas a quartile increase in 2-oxadipic acid and fumaric acid was negatively associated with the risk of PNs in multiple-metabolite models. A positive but insignificant joint associations of the mixture of 16 metabolites with PNs was observed by using QgC models analyses. Further studies are warranted to clarify the association between circulating metabolites and PNs and the biological mechanisms.
Collapse
Affiliation(s)
- Yue-yang Wu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Wen-bin Shen
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Jian-wei Li
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Meng-yu Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Wen-lei Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Sheng Wang
- The Center for Scientific Research of Anhui Medical University, Hefei, Anhui, China
| | - Jian-jun Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Fen Huang
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China
| | - Qi-rong Qin
- Maanshan Center for Disease Control and Provention, Maanshan, Anhui, China
| |
Collapse
|
7
|
Kwee TC, Yakar D, Sluijter TE, Pennings JP, Roest C. Can we revolutionize diagnostic imaging by keeping Pandora's box closed? Br J Radiol 2023; 96:20230505. [PMID: 37906185 PMCID: PMC10646642 DOI: 10.1259/bjr.20230505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 08/15/2023] [Accepted: 09/09/2023] [Indexed: 11/02/2023] Open
Abstract
Incidental imaging findings are a considerable health problem, because they generally result in low-value and potentially harmful care. Healthcare professionals struggle how to deal with them, because once detected they can usually not be ignored. In this opinion article, we first reflect on current practice, and then propose and discuss a new potential strategy to pre-emptively tackle incidental findings. The core principle of this concept is to keep the proverbial Pandora's box closed, i.e. to not visualize incidental findings, which can be achieved using deep learning algorithms. This concept may have profound implications for diagnostic imaging.
Collapse
Affiliation(s)
- Thomas C Kwee
- Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Derya Yakar
- Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Tim E Sluijter
- Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Jan P Pennings
- Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - Christian Roest
- Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| |
Collapse
|
8
|
Susai CJ, Velotta JB, Sakoda LC. Clinical Adjuncts to Lung Cancer Screening: A Narrative Review. Thorac Surg Clin 2023; 33:421-432. [PMID: 37806744 PMCID: PMC10926946 DOI: 10.1016/j.thorsurg.2023.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/10/2023]
Abstract
The updated US Preventive Services Task Force guidelines on lung cancer screening have significantly expanded the population of screening eligible adults, among whom the balance of benefits and harms associated with lung cancer screening vary considerably. Clinical adjuncts are additional information and tools that can guide decision-making to optimally screen individuals who are most likely to benefit. Proposed adjuncts include integration of clinical history, risk prediction models, shared-decision-making tools, and biomarker tests at key steps in the screening process. Although evidence regarding their clinical utility and implementation is still evolving, they carry significant promise in optimizing screening effectiveness and efficiency for lung cancer.
Collapse
Affiliation(s)
- Cynthia J Susai
- UCSF East Bay General Surgery, 1411 East 31st Street QIC 22134, Oakland, CA 94612, USA
| | - Jeffrey B Velotta
- Department of Thoracic Surgery, Kaiser Permanente Northern California, 3600 Broadway, Oakland, CA 94611, USA
| | - Lori C Sakoda
- Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA.
| |
Collapse
|
9
|
Godfrey CM, Shipe ME, Welty VF, Maiga AW, Aldrich MC, Montgomery C, Crockett J, Vaszar LT, Regis S, Isbell JM, Rickman OB, Pinkerman R, Lambright ES, Nesbitt JC, Maldonado F, Blume JD, Deppen SA, Grogan EL. The Thoracic Research Evaluation and Treatment 2.0 Model: A Lung Cancer Prediction Model for Indeterminate Nodules Referred for Specialist Evaluation. Chest 2023; 164:1305-1314. [PMID: 37421973 PMCID: PMC10635839 DOI: 10.1016/j.chest.2023.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 05/03/2023] [Accepted: 06/01/2023] [Indexed: 07/10/2023] Open
Abstract
BACKGROUND Appropriate risk stratification of indeterminate pulmonary nodules (IPNs) is necessary to direct diagnostic evaluation. Currently available models were developed in populations with lower cancer prevalence than that seen in thoracic surgery and pulmonology clinics and usually do not allow for missing data. We updated and expanded the Thoracic Research Evaluation and Treatment (TREAT) model into a more generalized, robust approach for lung cancer prediction in patients referred for specialty evaluation. RESEARCH QUESTION Can clinic-level differences in nodule evaluation be incorporated to improve lung cancer prediction accuracy in patients seeking immediate specialty evaluation compared with currently available models? STUDY DESIGN AND METHODS Clinical and radiographic data on patients with IPNs from six sites (N = 1,401) were collected retrospectively and divided into groups by clinical setting: pulmonary nodule clinic (n = 374; cancer prevalence, 42%), outpatient thoracic surgery clinic (n = 553; cancer prevalence, 73%), or inpatient surgical resection (n = 474; cancer prevalence, 90%). A new prediction model was developed using a missing data-driven pattern submodel approach. Discrimination and calibration were estimated with cross-validation and were compared with the original TREAT, Mayo Clinic, Herder, and Brock models. Reclassification was assessed with bias-corrected clinical net reclassification index and reclassification plots. RESULTS Two-thirds of patients had missing data; nodule growth and fluorodeoxyglucose-PET scan avidity were missing most frequently. The TREAT version 2.0 mean area under the receiver operating characteristic curve across missingness patterns was 0.85 compared with that of the original TREAT (0.80), Herder (0.73), Mayo Clinic (0.72), and Brock (0.68) models with improved calibration. The bias-corrected clinical net reclassification index was 0.23. INTERPRETATION The TREAT 2.0 model is more accurate and better calibrated for predicting lung cancer in high-risk IPNs than the Mayo, Herder, or Brock models. Nodule calculators such as TREAT 2.0 that account for varied lung cancer prevalence and that consider missing data may provide more accurate risk stratification for patients seeking evaluation at specialty nodule evaluation clinics.
Collapse
Affiliation(s)
- Caroline M Godfrey
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Maren E Shipe
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Valerie F Welty
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Amelia W Maiga
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; Division of Thoracic Surgery, Veterans Hospital, Tennessee Valley Healthcare System, Nashville, TN
| | - Melinda C Aldrich
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | | | - Jerod Crockett
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | | | - Shawn Regis
- Department of Radiation Oncology, Lahey Hospital and Medical Center, Burlington, MA
| | - James M Isbell
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Otis B Rickman
- Division of Pulmonary Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Rhonda Pinkerman
- Division of Thoracic Surgery, Veterans Hospital, Tennessee Valley Healthcare System, Nashville, TN
| | - Eric S Lambright
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Jonathan C Nesbitt
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; Division of Thoracic Surgery, Veterans Hospital, Tennessee Valley Healthcare System, Nashville, TN
| | - Fabien Maldonado
- Division of Pulmonary Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Jeffrey D Blume
- School of Data Science, University of Virginia, Charlottesville, VA
| | - Stephen A Deppen
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN
| | - Eric L Grogan
- Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN; Division of Thoracic Surgery, Veterans Hospital, Tennessee Valley Healthcare System, Nashville, TN.
| |
Collapse
|
10
|
Liao Z, Zheng R, Li N, Shao G. Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study. BMC Cancer 2023; 23:872. [PMID: 37718448 PMCID: PMC10506295 DOI: 10.1186/s12885-023-11385-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 09/07/2023] [Indexed: 09/19/2023] Open
Abstract
BACKGROUND Lung cancer is a major global threat to public health for which a novel predictive nomogram is urgently needed. Non-small cell lung cancer (NSCLC) which accounts for the main port of lung cancer cases is attracting more and more people's attention. PATIENTS AND METHODS Here, we designed a novel predictive nomogram using a design dataset consisting of 515 pulmonary nodules, with external validation being performed using a separate dataset consisting of 140 nodules and a separate dataset consisting of 237 nodules. The selection of significant variables for inclusion in this model was achieved using a least absolute shrinkage and selection operator (LASSO) logistic regression model, after which a corresponding nomogram was developed. C-index values, calibration plots, and decision curve analyses were used to gauge the discrimination, calibration, and clinical utility, respectively, of this predictive model. Validation was then performed with the internal bootstrapping validation and external cohorts. RESULTS A predictive nomogram was successfully constructed incorporating hypertension status, plasma fibrinogen levels, blood urea nitrogen (BUN), density, ground-glass opacity (GGO), and pulmonary nodule size as significant variables associated with nodule status. This model exhibited good discriminative ability, with a C-index value of 0.765 (95% CI: 0.722-0.808), and was well-calibrated. In validation analyses, this model yielded C-index values of 0.892 (95% CI: 0.844-0.940) for external cohort and 0.853 (95% CI: 0.807-0.899) for external cohort 2. In the internal bootstrapping validation, C-index value could still reach 0.753. Decision curve analyses supported the clinical value of this predictive nomogram when used at a NSCLC possibility threshold of 18%. CONCLUSION The nomogram constructed in this study, which incorporates hypertension status, plasma fibrinogen levels, BUN, density, GGO status, and pulmonary nodule size, was able to reliably predict NSCLC risk in this Chinese cohort of patients presenting with pulmonary nodules.
Collapse
Affiliation(s)
- Zufang Liao
- The Affiliated Lihuili Hospital, Ningbo University, Ningbo, 315041, Zhejiang, China
| | - Rongjiong Zheng
- Ningbo Yinzhou NO.2 Hospital, Ningbo, 315192, Zhejiang, China
| | - Ni Li
- Department of Cardiothoracic Surgery, Li Huili Hospital Affiliated to Ningbo University, Xingning Road 57, Ningbo, 315041, Zhejiang, China
| | - Guofeng Shao
- Department of Cardiothoracic Surgery, Li Huili Hospital Affiliated to Ningbo University, Xingning Road 57, Ningbo, 315041, Zhejiang, China.
| |
Collapse
|
11
|
Vachani A, Lam S, Massion PP, Brown JK, Beggs M, Fish AL, Carbonell L, Wang SX, Mazzone PJ. Development and Validation of a Risk Assessment Model for Pulmonary Nodules Using Plasma Proteins and Clinical Factors. Chest 2023; 163:966-976. [PMID: 36368616 PMCID: PMC10258433 DOI: 10.1016/j.chest.2022.10.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 10/22/2022] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Deficiencies in risk assessment for patients with pulmonary nodules (PNs) contribute to unnecessary invasive testing and delays in diagnosis. RESEARCH QUESTION What is the accuracy of a novel PN risk model that includes plasma proteins and clinical factors? How does the accuracy compare with that of an established risk model? STUDY DESIGN AND METHODS Based on technology using magnetic nanosensors, assays were developed with seven plasma proteins. In a training cohort (n = 429), machine learning approaches were used to identify an optimal algorithm that subsequently was evaluated in a validation cohort (n = 489), and its performance was compared with the Mayo Clinic model. RESULTS In the training set, we identified a support vector machine algorithm that included the seven plasma proteins and six clinical factors that demonstrated an area under the receiver operating characteristic curve of 0.87 and met other selection criteria. The resulting risk reclassification model (RRM) was used to recategorize patients with a pretest risk of between 10% and 84%, and its performance was assessed across five risk strata (low, ≤ 10%; moderate, 10%-34%; intermediate, 35%-70%; high, 71%-84%; very high, > 85%). Stratification by the RRM decreased the proportion of intermediate-risk patients from 26.7% to 10.8% (P < .001) and increased the low-risk and high-risk strata from 16.8% to 21.9% (P < .001) and from 3.7% to 12.1% (P < .001), respectively. Among patients classified as low risk by the RRM and Mayo Clinic model, the corresponding true-negative to false-negative ratios were 16.8 and 19.5, respectively. Among patients classified as very high risk by the RRM and Mayo Clinic model, the corresponding true-positive to false-positive ratios were 28.5 and 17.0, respectively. Compared with the Mayo Clinic model, the RRM provided higher specificity at the low-risk threshold and higher sensitivity at the very high-risk threshold. INTERPRETATION The RRM accurately reclassified some patients into low-risk and very high-risk categories, suggesting the potential to improve PN risk assessment.
Collapse
Affiliation(s)
- Anil Vachani
- Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA; Corporal Michael J. Crescenz VA Medical Center, Department of Medicine, Philadelphia, PA.
| | - Stephen Lam
- Department of Integrative Oncology, British Columbia Cancer Research Institute, University of British Columbia, Vancouver, BC, Canada
| | - Pierre P Massion
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN
| | - James K Brown
- Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, CA; VA Medical Center San Francisco, Department of Medicine, San Francisco, CA
| | | | | | | | | | | |
Collapse
|
12
|
Farjah F, Monsell SE, Greenlee RT, Gould MK, Smith-Bindman R, Banegas MP, Schoen K, Ramaprasan A, Buist DSM. Patient and Nodule Characteristics Associated With a Lung Cancer Diagnosis Among Individuals With Incidentally Detected Lung Nodules. Chest 2023; 163:719-730. [PMID: 36191633 PMCID: PMC10154904 DOI: 10.1016/j.chest.2022.09.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 08/23/2022] [Accepted: 09/09/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Pulmonary nodules are a common incidental finding on CT imaging. Few studies have described patient and nodule characteristics associated with a lung cancer diagnosis using a population-based cohort. RESEARCH QUESTION Does a relationship exist between patient and nodule characteristics and lung cancer among individuals with incidentally detected pulmonary nodules, and can this information be used to create exploratory lung cancer prediction models with reasonable performance characteristics? STUDY DESIGN AND METHODS We conducted a retrospective cohort study of adults older than 18 years with lung nodules of any size incidentally detected by chest CT imaging between 2005 and 2015. All patients had at least 2 years of complete follow-up. To evaluate the relationship between patient and nodule characteristics and lung cancer, we used binomial regression. We used logistic regression to create prediction models, and we internally validated model performance using bootstrap optimism correction. RESULTS Among 7,240 patients with a median age of 67 years, 56% of whom were women, with a median BMI of 28 kg/m2, 56% of whom were ever smokers, 31% of whom had prior nonlung malignancy, with a median nodule size 5.6 mm, 57% of whom had multiple nodules, and 40% of whom had an upper lobe nodule, 265 patients (3.7%; 95% CI, 3.2%-4.1%) had a diagnosis of lung cancer. In a multivariate analysis, age, sex, BMI, smoking history, and nodule size and location were associated with a lung cancer diagnosis, whereas prior malignancy and nodule number and laterality were not. We were able to construct two prediction models with an area under the curve value of 0.75 (95% CI, 0.72-0.80) and reasonable calibration. INTERPRETATION Lung cancer is uncommon among individuals with incidentally detected lung nodules. Some, but not all, previously identified factors associated with lung cancer also were associated with this outcome in this sample. These findings may have implications for clinical practice, future practice guidelines, and the development of novel lung cancer prediction models for individuals with incidentally detected lung nodules.
Collapse
Affiliation(s)
- Farhood Farjah
- Department of Surgery, University of Washington, Seattle, WA.
| | - Sarah E Monsell
- Department of Biostatistics, University of Washington, Seattle, WA
| | | | - Michael K Gould
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA
| | - Rebecca Smith-Bindman
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
| | - Matthew P Banegas
- Department of Radiation Medicine and Applied Sciences, University of San Diego, San Diego, CA
| | - Kurt Schoen
- Marshfield Clinic Research Institute, Marshfield, WI
| | | | - Diana S M Buist
- Kaiser Permanente Washington Health Research Institute, Seattle, WA
| |
Collapse
|
13
|
Osarogiagbon RU, Liao W, Faris NR, Fehnel C, Goss J, Shepherd CJ, Qureshi T, Matthews AT, Smeltzer MP, Pinsky PF. Evaluation of Lung Cancer Risk Among Persons Undergoing Screening or Guideline-Concordant Monitoring of Lung Nodules in the Mississippi Delta. JAMA Netw Open 2023; 6:e230787. [PMID: 36848089 PMCID: PMC9972195 DOI: 10.1001/jamanetworkopen.2023.0787] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/01/2023] Open
Abstract
IMPORTANCE Guideline-concordant management of lung nodules promotes early lung cancer diagnosis, but the lung cancer risk profile of persons with incidentally detected lung nodules differs from that of screening-eligible persons. OBJECTIVE To compare lung cancer diagnosis hazard between participants receiving low-dose computed tomography screening (LDCT cohort) and those in a lung nodule program (LNP cohort). DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study included LDCT vs LNP enrollees from January 1, 2015, to December 31, 2021, who were seen in a community health care system. Participants were prospectively identified, data were abstracted from clinical records, and survival was updated at 6-month intervals. The LDCT cohort was stratified by Lung CT Screening Reporting and Data System as having no potentially malignant lesions (Lung-RADS 1-2 cohort) vs those with potentially malignant lesions (Lung-RADS 3-4 cohort), and the LNP cohort was stratified by smoking history into screening-eligible vs screening-ineligible groups. Participants with prior lung cancer, younger than 50 years or older than 80 years, and lacking a baseline Lung-RADS score (LDCT cohort only) were excluded. Participants were followed up to January 1, 2022. MAIN OUTCOMES AND MEASURES Comparative cumulative rates of lung cancer diagnosis and patient, nodule, and lung cancer characteristics between programs, using LDCT as a reference. RESULTS There were 6684 participants in the LDCT cohort (mean [SD] age, 65.05 [6.11] years; 3375 men [50.49%]; 5774 [86.39%] in the Lung-RADS 1-2 and 910 [13.61%] in the Lung-RADS 3-4 cohorts) and 12 645 in the LNP cohort (mean [SD] age, 65.42 [8.33] years; 6856 women [54.22%]; 2497 [19.75%] screening eligible and 10 148 [80.25%] screening ineligible). Black participants constituted 1244 (18.61%) of the LDCT cohort, 492 (19.70%) of the screening-eligible LNP cohort, and 2914 (28.72%) of the screening-ineligible LNP cohort (P < .001). The median lesion size was 4 (IQR, 2-6) mm for the LDCT cohort (3 [IQR, 2-4] mm for Lung-RADS 1-2 and 9 [IQR, 6-15] mm for Lung-RADS 3-4 cohorts), 9 (IQR, 6-16) mm for the screening-eligible LNP cohort, and 7 (IQR, 5-11) mm for the screening-ineligible LNP cohort. In the LDCT cohort, lung cancer was diagnosed in 80 participants (1.44%) in the Lung-RADS 1-2 cohort and 162 (17.80%) in the Lung-RADS 3-4 cohort; in the LNP cohort, it was diagnosed in 531 (21.27%) in the screening-eligible cohort and 447 (4.40%) in the screening-ineligible cohort. Compared with Lung-RADS 1-2, the fully adjusted hazard ratios (aHRs) were 16.2 (95% CI, 12.7-20.6) for the screening-eligible cohort and 3.8 (95% CI, 3.0-5.0) for the screening-ineligible cohort; compared with Lung-RADS 3-4, the aHRs were 1.2 (95% CI, 1.0-1.5) and 0.3 (95% CI, 0.2-0.4), respectively. The stage of lung cancer was I to II in 156 of 242 patients (64.46%) in the LDCT cohort, 276 of 531 (52.00%) in the screening-eligible LNP cohort, and 253 of 447 (56.60%) in the screening-ineligible LNP cohort. CONCLUSIONS AND RELEVANCE In this cohort study, the cumulative lung cancer diagnosis hazard of screening-age persons enrolled in the LNP was higher than that in a screening cohort, irrespective of smoking history. The LNP provided access to early detection for a higher proportion of Black persons.
Collapse
Affiliation(s)
- Raymond U. Osarogiagbon
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Wei Liao
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Nicholas R. Faris
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Carrie Fehnel
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Jordan Goss
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Catherine J. Shepherd
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Talat Qureshi
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | - Anberitha T. Matthews
- Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee
| | | | - Paul F. Pinsky
- Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
14
|
Quantitative CT analysis of lung parenchyma to improve malignancy risk estimation in incidental pulmonary nodules. Eur Radiol 2022; 33:3908-3917. [PMID: 36538071 PMCID: PMC10181968 DOI: 10.1007/s00330-022-09334-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 11/18/2022] [Accepted: 11/29/2022] [Indexed: 12/24/2022]
Abstract
Abstract
Objectives
To assess the value of quantitative computed tomography (QCT) of the whole lung and nodule-bearing lobe regarding pulmonary nodule malignancy risk estimation.
Methods
A total of 251 subjects (median [IQR] age, 65 (57–73) years; 37% females) with pulmonary nodules on non-enhanced thin-section CT were retrospectively included. Twenty percent of the nodules were malignant, the remainder benign either histologically or at least 1-year follow-up. CT scans were subjected to in-house software, computing parameters such as mean lung density (MLD) or peripheral emphysema index (pEI). QCT variable selection was performed using logistic regression; selected variables were integrated into the Mayo Clinic and the parsimonious Brock Model.
Results
Whole-lung analysis revealed differences between benign vs. malignant nodule groups in several parameters, e.g. the MLD (−766 vs. −790 HU) or the pEI (40.1 vs. 44.7 %). The proposed QCT model had an area-under-the-curve (AUC) of 0.69 (95%-CI, 0.62−0.76) based on all available data. After integrating MLD and pEI into the Mayo Clinic and Brock Model, the AUC of both clinical models improved (AUC, 0.91 to 0.93 and 0.88 to 0.91, respectively). The lobe-specific analysis revealed that the nodule-bearing lobes had less emphysema than the rest of the lung regarding benign (EI, 0.5 vs. 0.7 %; p < 0.001) and malignant nodules (EI, 1.2 vs. 1.7 %; p = 0.001).
Conclusions
Nodules in subjects with higher whole-lung metrics of emphysema and less fibrosis are more likely to be malignant; hereby the nodule-bearing lobes have less emphysema. QCT variables could improve the risk assessment of incidental pulmonary nodules.
Key Points
• Nodules in subjects with higher whole-lung metrics of emphysema and less fibrosis are more likely to be malignant.
• The nodule-bearing lobes have less emphysema compared to the rest of the lung.
• QCT variables could improve the risk assessment of incidental pulmonary nodules.
Collapse
|
15
|
Liao Z, Zheng R, Shao G. A lung cancer risk prediction model for nonsmokers: A retrospective analysis of lung nodule cohorts in China. J Clin Lab Anal 2022; 36:e24748. [DOI: 10.1002/jcla.24748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 10/12/2022] [Accepted: 10/13/2022] [Indexed: 11/06/2022] Open
Affiliation(s)
- Zufang Liao
- The Affiliated Lihuili Hospital Ningbo University Ningbo China
| | | | - Guofeng Shao
- Department of Cardiothoracic Surgery Li Huili Hospital Affiliated to Ningbo University Ningbo China
| |
Collapse
|
16
|
Kim RY, Oke JL, Pickup LC, Munden RF, Dotson TL, Bellinger CR, Cohen A, Simoff MJ, Massion PP, Filippini C, Gleeson FV, Vachani A. Artificial Intelligence Tool for Assessment of Indeterminate Pulmonary Nodules Detected with CT. Radiology 2022; 304:683-691. [PMID: 35608444 PMCID: PMC9434821 DOI: 10.1148/radiol.212182] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 03/02/2022] [Accepted: 03/16/2022] [Indexed: 12/25/2022]
Abstract
Background Limited data are available regarding whether computer-aided diagnosis (CAD) improves assessment of malignancy risk in indeterminate pulmonary nodules (IPNs). Purpose To evaluate the effect of an artificial intelligence-based CAD tool on clinician IPN diagnostic performance and agreement for both malignancy risk categories and management recommendations. Materials and Methods This was a retrospective multireader multicase study performed in June and July 2020 on chest CT studies of IPNs. Readers used only CT imaging data and provided an estimate of malignancy risk and a management recommendation for each case without and with CAD. The effect of CAD on average reader diagnostic performance was assessed using the Obuchowski-Rockette and Dorfman-Berbaum-Metz method to calculate estimates of area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. Multirater Fleiss κ statistics were used to measure interobserver agreement for malignancy risk and management recommendations. Results A total of 300 chest CT scans of IPNs with maximal diameters of 5-30 mm (50.0% malignant) were reviewed by 12 readers (six radiologists, six pulmonologists) (patient median age, 65 years; IQR, 59-71 years; 164 [55%] men). Readers' average AUC improved from 0.82 to 0.89 with CAD (P < .001). At malignancy risk thresholds of 5% and 65%, use of CAD improved average sensitivity from 94.1% to 97.9% (P = .01) and from 52.6% to 63.1% (P < .001), respectively. Average reader specificity improved from 37.4% to 42.3% (P = .03) and from 87.3% to 89.9% (P = .05), respectively. Reader interobserver agreement improved with CAD for both the less than 5% (Fleiss κ, 0.50 vs 0.71; P < .001) and more than 65% (Fleiss κ, 0.54 vs 0.71; P < .001) malignancy risk categories. Overall reader interobserver agreement for management recommendation categories (no action, CT surveillance, diagnostic procedure) also improved with CAD (Fleiss κ, 0.44 vs 0.52; P = .001). Conclusion Use of computer-aided diagnosis improved estimation of indeterminate pulmonary nodule malignancy risk on chest CT scans and improved interobserver agreement for both risk stratification and management recommendations. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Yanagawa in this issue.
Collapse
Affiliation(s)
- Roger Y. Kim
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Jason L. Oke
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Lyndsey C. Pickup
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Reginald F. Munden
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Travis L. Dotson
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Christina R. Bellinger
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Avi Cohen
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Michael J. Simoff
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Pierre P. Massion
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Claire Filippini
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Fergus V. Gleeson
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| | - Anil Vachani
- From the Division of Pulmonary, Allergy, and Critical Care,
Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Suite 216, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104 (R.Y.K.,
A.V.); Nuffield Department of Primary Care Health Sciences, University of
Oxford, Oxford, United Kingdom (J.L.O.); Optellum, Oxford, United Kingdom
(L.C.P.); Department of Radiology and Radiological Science, Medical University
of South Carolina, Charleston, SC (R.F.M.); Department of Pulmonary, Critical
Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine,
Winston-Salem, NC (T.L.D., C.R.B.); Division of Pulmonary and Critical Care
Medicine, Department of Medicine, Henry Ford Health System, Detroit, Mich (A.C.,
M.J.S.); Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt
Ingram Cancer Center, Nashville, Tenn (P.P.M.); and Department of Oncology,
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom (C.F.,
F.V.G.)
| |
Collapse
|
17
|
Papalampidou A, Papoutsi E, Katsaounou P. Pulmonary nodule malignancy probability: a diagnostic accuracy meta-analysis of the Mayo model. Clin Radiol 2022; 77:443-450. [DOI: 10.1016/j.crad.2022.01.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Accepted: 01/25/2022] [Indexed: 11/28/2022]
|